Core Viewpoint - Levi & Korsinsky has initiated an investigation into Ashford Hospitality Trust, Inc. for potential violations of federal securities laws [1] Group 1: Company Actions - Ashford Hospitality Trust announced the extension of its Highland mortgage loan secured by 18 hotels [2] - To maintain liquidity while evaluating strategic alternatives, Ashford has suspended preferred dividends for Series D, F, G, H, I, J, K, L, and M preferred stock, which were previously declared for record holders as of December 31, 2025, and due on January 15, 2026 [2] - Following the announcement of these actions, Ashford's stock price experienced a decline of over 8% on January 13, 2026 [2] Group 2: Legal and Investor Support - Investors who suffered losses on Ashford Hospitality Trust securities are encouraged to explore potential recovery options under federal securities laws [3] - Levi & Korsinsky is a well-established securities litigation firm with a strong track record in securing significant recoveries for shareholders [4]

Group 1 - The core issue being investigated is whether PennyMac Financial Services, Inc. complied with federal securities laws following a significant drop in pretax income [1] - For the fourth quarter and full-year 2025, PennyMac reported a 70 percent decrease in pretax income excluding valuation-related items compared to the prior quarter [1] - The decline in income was attributed to increased realization of mortgage servicing rights cash flows, driven by lower mortgage rates leading to higher prepayment activity [1] Group 2 - Following the announcement of the financial results, the stock price of PennyMac experienced a decline [1]

PHILADELPHIA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”) on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the “Class Period”), inclusive. Investor Deadline: Investors who purchased Integer securities during the Class Period may, no later than Februar ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Smart Digital Group Limited due to allegations of securities law violations, urging affected investors to contact them before the March 16, 2026 deadline for lead plaintiff applications in a federal class action lawsuit [4][6]. Group 1: Allegations Against Smart Digital - The complaint alleges that Smart Digital and its executives made false or misleading statements and failed to disclose significant risks related to market manipulation and fraudulent promotion schemes [6]. - Specific allegations include the use of social media misinformation and impersonation by individuals posing as financial professionals to manipulate the stock price [6]. - It is claimed that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, which was not disclosed in the company's public statements [6]. Group 2: Stock Price Collapse and SEC Actions - On September 26, 2025, Smart Digital's stock price fell by 86.4%, closing at $1.85 per share, following a trading halt by NASDAQ due to volatility [7]. - The SEC suspended trading of Smart Digital securities from September 29, 2025, to October 10, 2025, due to potential manipulation linked to social media recommendations that aimed to artificially inflate the stock price [7]. - Following the SEC's suspension, NASDAQ also suspended trading pending further information, and trading remains suspended with no clear end date [7]. Group 3: Class Action and Lead Plaintiff Information - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the class [8]. - Any member of the class can apply to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9]. - Faruqi & Faruqi encourages individuals with information regarding Smart Digital's conduct to come forward, including whistleblowers and former employees [9].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Wealthfront To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Wealthfront stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - January 27, 2026) - Faruqi ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BellRing Brands, Inc. for alleged violations of federal securities laws, particularly regarding misleading statements about sales growth and competition impacts [2][5]. Company Overview - BellRing Brands, Inc. trades on the NYSE under the ticker BRBR and has faced significant stock price declines due to disappointing sales performance and retailer inventory adjustments [2][6][7]. Legal Context - A federal securities class action has been filed against BellRing, with a deadline of March 23, 2026, for investors to seek the role of lead plaintiff [2][8]. - The complaint alleges that BellRing and its executives failed to disclose critical information regarding the sustainability of sales growth and the competitive landscape [5]. Stock Performance - On May 5, 2025, BellRing's stock dropped by $14.88, or 19%, following the announcement of reduced retailer inventory levels, closing at $63.55 per share [6]. - On August 4, 2025, the stock fell by $17.46, or nearly 33%, after disappointing quarterly consumption figures for Premier Protein RTD Shakes, closing at $36.18 per share [7]. Investor Communication - Faruqi & Faruqi encourages investors who suffered losses to contact them for discussions about their legal rights and options [1][9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bath & Body Works, Inc. due to allegations of misleading statements and failure to disclose critical information regarding the company's financial performance and business strategy [2][5]. Financial Performance - Bath & Body Works reported a 1% year-over-year decline in revenue for Q3 2025, missing prior guidance of 1-3% growth [6]. - The company's net income dropped by 26% to $77 million [6]. - The full-year earnings per diluted share outlook was sharply reduced from a range of $3.28 to $3.53 to "at least $2.83" [6]. Business Strategy - The company's strategy of pursuing "adjacencies, collaborations and promotions" was found to be ineffective in growing the customer base and delivering expected sales growth [5]. - Bath & Body Works admitted that this strategy led to reduced investment in core categories and an overreliance on brand collaborations to mask weak financial results [6]. Stock Market Reaction - Following the disappointing financial disclosures, Bath & Body Works' stock price fell by $5.22, or 24.8%, closing at $15.82 per share on November 20, 2025 [7].

Group 1 - Rezolute, Inc. shares experienced a significant decline on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for the drug candidate ersodetug, which is intended for treating congenital hyperinsulinism [5] - The clinical trial failed to meet both its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [5] - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. for investors who suffered significant losses [2][4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bitdeer Technologies Group due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's SEALMINER A4 project and its delayed product development [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the February 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Bitdeer [4]. - Investors who suffered losses in Bitdeer between June 6, 2024, and November 10, 2025, are encouraged to contact the firm to discuss their legal rights [1][4]. Group 2: Financial Performance and Stock Impact - Bitdeer reported a third-quarter earnings per share of -$1.28, missing the consensus estimate of -$0.22, which led to a stock price drop of $2.63 per share, or 14.9%, closing at $15.02 on November 11, 2025 [7]. - Following a fire incident at its construction facility, Bitdeer's stock fell another $2.83 per share, or 20.3%, closing at $11.11 on November 13, 2025 [8]. Group 3: Company Operations and Product Development - The complaint alleges that Bitdeer and its executives failed to disclose critical information regarding the SEAL04 chip's readiness and the expected mass production timeline, which was projected to begin in the second quarter of 2025 [6].

Core Viewpoint - Aquestive Therapeutics, Inc. has faced a significant decline in its stock price due to the FDA identifying deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the upcoming PDUFA action date [5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions [5]. - The company's stock is traded on NASDAQ under the ticker symbol AQST [4]. Group 2: Recent Developments - Shares of Aquestive Therapeutics plunged approximately 40% intraday following the FDA's notification regarding deficiencies in its New Drug Application for Anaphylm [5]. - The FDA's findings currently prevent discussions on labeling and post-marketing requirements, which raises concerns about the application's likelihood of approval [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses due to the recent stock decline [4][5]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].